Q-omics provides the consensus-scored RPS20P10 profile across patient tissues and cancer cell-line models. RPS20P10 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RPS20P10 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, RPS20P10 RNA expression shows 10,410 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, COAD, and THYM as cancer lineages where RPS20P10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS20P10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS20P10 survival associations across molecular data types. RPS20P10 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS20P10 RNA expression–survival associations across cancer types. High RPS20P10 expression shows unfavorable associations in UVM, ACC and KIRP, but favorable associations in CESC, LUSC and MESO. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .007). Together, the overview and detailed table identify UVM as the clearest survival context for RPS20P10 RNA expression.
This table summarizes RPS20P10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPS20P10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS20P10 shows lower tumor expression in BLCA and higher tumor expression in COAD, KIRC, LIHC, CHOL and THCA. The COAD box plot shows higher RPS20P10 RNA expression in tumor versus normal tissue (log2 FC = +0.526, t-test p < 0.001).
This table shows molecular features associated with RPS20P10 in patient tissues and cancer cell lines. In patient samples, RPS20P10 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
